Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.74 |
| ▸ | IDO1 | P14902 | 7/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NOS3 | P29474 | 5/20 | 0.57 |
| ▸ | NOS1 | P29475 | 5/20 | 0.57 |
| ▸ | NOS2 | P35228 | 5/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2953606 | 1.00 | KMO (0.74) | KMOIDO1KMT2AMEN1NOS3 | |
| SCHEMBL2978251 | 0.88 | PIK3CB (0.58) | KMOIDO1KMT2AMEN1HSD17B10 | |
| SCHEMBL4427326 | 0.87 | IDO1 (0.71) | KMOIDO1KMT2AMEN1NOS3 | |
| SCHEMBL29958110 | 0.87 | IDO1 (0.71) | KMOIDO1KMT2AMEN1NOS3 | |
| SCHEMBL16823385 | 0.85 | KMO (1.00) | KMOIDO1KMT2AMEN1TMEM97 | |
| SCHEMBL4425116 | 0.83 | KMT2A (0.66) | KMOIDO1KMT2AMEN1NOS3 | |
| SCHEMBL5416540 | 0.82 | CBX7 (0.62) | KMOIDO1KMT2AMEN1 | |
| SCHEMBL5289472 | 0.82 | MIF (0.63) | KMOKMT2AMEN1ALDH1A1 | |
| SCHEMBL30660242 | 0.82 | CBX7 (0.62) | KMOIDO1KMT2AMEN1 | |
| SCHEMBL11134988 | 0.81 | KMO (0.81) | KMOIDO1KMT2AMEN1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197756-A1 | PLASMA KALLIKREIN INHIBITORS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| CN-111205292-B | Imidazodinitrogen compound | 安斯泰来制药有限公司 | 2022-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KMO 204/4885IDO1 1698/4885KMT2A 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.